阿瑞匹坦联合地塞米松及昂丹司琼预防妇科肿瘤患者顺铂化疗引起的恶心呕吐的效果观察

发布时间：2018-05-03 04:26

本文选题：化疗引起的恶心呕吐 + 预防性治疗　；参考：《实用妇产科杂志》2017年01期

【摘要】：目的:通过前瞻性观察评价阿瑞匹坦联合地塞米松及昂丹司琼预防妇科肿瘤患者接受含顺铂化疗引起的恶心呕吐(CINV)的效果。方法:采用前瞻性研究方法选择2013年12月1日至2014年9月30日收治的妇科肿瘤患者70例,均接受含有顺铂的单日或多日化疗方案,并给予阿瑞匹坦联合地塞米松及昂丹司琼的三联预防性止吐治疗。在整个研究期间通过患者研究日志记录其对治疗的反应。主要研究终点为完全缓解率,次要研究终点包括急性期完全缓解率、延迟期完全缓解率、完全保护率、完全控制率、危险因素和预期因素对完全缓解率的影响以及CINV对日常生活的影响。结果:70例患者中完全缓解率为80.0%,急性期完全缓解率为94.3%,延迟期完全缓解率为84.3%;完全保护率为42.9%,完全控制率为25.7%;71.4%的患者表示CINV对日常生活影响极小。结论:阿瑞匹坦联合地塞米松及昂丹司琼可有效预防妇科肿瘤患者接受含顺铂的化疗引起的呕吐,但三药联合方案对预防恶心的作用仍欠满意,用于多日化疗的最佳用药方案尚需进一步研究。接受顺铂化疗的妇科肿瘤患者,在应用三联止吐方案后,CINV对多数患者生活质量的影响很小。
[Abstract]:Objective: to evaluate the effect of combination of amipitan and dexamethasone and ondansetron in the prevention of nausea and vomiting induced by chemotherapy with cisplatin in patients with gynecological neoplasms. Methods: a prospective study was used to select 70 patients with gynecological neoplasms admitted from December 1, 2013 to September 30, 2014. All patients received a single or multiple day chemotherapy regimen containing cisplatin. The patients were treated with albitam combined with dexamethasone and ondansetron. Responses to treatment were recorded in patient study logs throughout the study period. The main endpoint of the study is the complete remission rate. The secondary study endpoint includes the complete remission rate in the acute phase, the complete remission rate in the delayed period, the complete protection rate, and the complete control rate. The effects of risk factors and expected factors on the complete remission rate and the effects of CINV on daily life. Results the complete remission rate was 80.0 in 70 patients, the complete remission rate in acute stage was 94.3, the complete remission rate in delayed period was 84.3, the complete protection rate was 42.9 and the complete control rate was 25.71.4%, the effect of CINV on daily life was minimal. Conclusion: Arepitan combined with dexamethasone and ondansetron can effectively prevent vomiting caused by chemotherapy containing cisplatin in patients with gynecological neoplasms. The best regimen for multi-day chemotherapy needs further study. CINV had little effect on the quality of life of most patients with gynecological tumors who received cisplatin chemotherapy after triple antiemetic therapy.
【作者单位】：北京大学肿瘤医院暨北京市肿瘤防治研究所恶性肿瘤发病机制及转化研究教育部重点实验室;
【分类号】：R737.3

【参考文献】